Phase I Dose-Escalation Study of Nimustine in Tumor-Bearing Dogs

Nimustine (ACNU) is an alkylating agent of the nitrosourea and can be an antineoplastic agent in dogs. But, there has been no report on its dose-limiting toxicity (DLT) in dogs. This study was a phase I dose-escalation clinical trial to determine the maximum tolerated dose (MTD) and DLT of ACNU in t...

Descripción completa

Detalles Bibliográficos
Autores principales: TAKAHASHI, Masashi, GOTO-KOSHINO, Yuko, FUKUSHIMA, Kenjiro, KANEMOTO, Hideyuki, NAKASHIMA, Ko, FUJINO, Yasuhito, OHNO, Koichi, ENDO, Yasuyuki, TSUJIMOTO, Hajime
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Veterinary Science 2014
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108775/
https://www.ncbi.nlm.nih.gov/pubmed/24521794
http://dx.doi.org/10.1292/jvms.13-0345
Descripción
Sumario:Nimustine (ACNU) is an alkylating agent of the nitrosourea and can be an antineoplastic agent in dogs. But, there has been no report on its dose-limiting toxicity (DLT) in dogs. This study was a phase I dose-escalation clinical trial to determine the maximum tolerated dose (MTD) and DLT of ACNU in tumor-bearing dogs. The starting dosage was 25 mg/m(2), and subsequent dosages were administered in increments of 5 mg/m(2) in cohort of 3 dogs. Eight dogs were included, the MTD was determined to be 25 mg/m(2), DLT was neutropenia, and the optimal interval was considered to be 21 days. The data herein provide a basis for the subsequent phase II trial of ACNU in dogs.

Ejemplares similares